Bispecific Antibodies Combining Checkpoint Blockade and T-Cell Costimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tumor-reactive T cells lose their cytotoxic ability over time due to up-regulation of inhibitory immune checkpoints such as PD-1 and CTLA-4, with existing therapies only showing response in a subset of patients, typically ranging from 10 to 30%.
Innovation Solution
Development of bispecific antibodies that bind to both costimulatory receptors (e.g. ICOS, GITR, OX40, 4-1BB) and checkpoint receptors (e.g. PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT) to activate T cells for cancer treatment, utilizing heterodimeric antibody formats with specific amino acid sequences and modifications to enhance functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monotherapies (anti-CTLA4 or anti-PD1 antibodies) are used to block immune checkpoints, then T cell activation is stimulated and anti-tumor responses are induced, but response rates are limited to 10-30% of patients
Solution Approach 1:
The patent combines immune checkpoint blockade (e.g., anti-PD-1) and T cell costimulation (e.g., anti-ICOS) into a single bispecific antibody molecule. This merging of two separate therapeutic mechanisms into one agent allows simultaneous delivery of both inhibitory blockade and costimulatory signals to T cells, thereby expanding the fraction of patients who respond to therapy while maintaining the individual efficacy of each mechanism.
Solution Approach 2:
The bispecific antibody is designed to perform multiple functions: it blocks immune checkpoint inhibition while simultaneously providing costimulatory signals to T cells. This multi-functionality enables a single therapeutic agent to address multiple aspects of T cell regulation, potentially converting more non-responders to responders and expanding the overall therapeutic coverage beyond what monotherapies achieve.
2Reliability
If combination therapy with multiple antibodies is used to overcome limited response rates, then anti-tumor efficacy is enhanced, but treatment complexity and patient burden increase
Solution Approach 1:
The patent merges the functions of multiple separate antibodies (checkpoint blocker and costimulatory agonist) into a single bispecific antibody molecule. This consolidation reduces treatment complexity by eliminating the need for multiple infusions, separate dosing schedules, and coordinated administration of multiple agents, while maintaining the enhanced anti-tumor efficacy that combination therapy provides.
Solution Approach 2:
The bispecific antibody serves as a universal therapeutic agent that integrates multiple mechanisms of action within one molecule. This multi-functionality simplifies the treatment regimen by providing both checkpoint blockade and costimulation through a single administration, reducing patient burden and clinical management complexity compared to traditional combination therapy with separate antibodies.
3Reliability
If bisspecific antibodies binding both costimulatory and checkpoint receptors are developed, then T cell activation is enhanced and anti-tumor responses are improved, but antibody structure and manufacturing complexity increase
Solution Approach 1:
The patent employs engineered antibody formats (such as heterodimeric IgG structures with specific Fc domain mutations) that enable the merging of two distinct antigen-binding specificities into a single functional molecule. These structural designs, including mutations like L368D/K370S and S364K/E357Q in the Fc regions, facilitate controlled heterodimer formation while maintaining stability and manufacturability, thus achieving enhanced T cell activation without prohibitively increasing manufacturing complexity.
Solution Approach 2:
The patent utilizes specific amino acid sequence modifications and structural parameter changes in the antibody constant regions to control heterodimer formation and stability. By adjusting parameters such as Fc domain mutations, pH stability, and binding affinity characteristics, the patent optimizes the bispecific antibody structure to achieve the desired dual functionality while maintaining feasibility for industrial production and clinical use.
Data Source
Figure 1
Figure 2A~2F
Figure 2G~2L
AI summary
The present invention is directed to bispedfic, heterodimeric immunomodulatory antibodies.